På grund af muligheden for behandling med større doser kemoterapi (fx opretholde fuld dosering i behandlingsplanen) kan patienten have en øget risiko for at få trombocytopeni og anæmi.
Because of the potential of receiving higher doses of chemotherapy (e. g. full doses on the prescribed schedule) the patient may be at greater risk of thrombocytopenia and anaemia.